clinical trial · NCT05375994
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Non Small Cell Lung CancerKRAS Activating MutationAdvanced CancerMetastatic CancerMalignant Neoplasm of LungMalignant Neoplastic Diseaseavutometinib (VS-6766) and adagrasib
brief summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
started
Aug 1, 2022
primary completion
Dec 24, 2025
completion
Jan 1, 2026
last updated
May 18, 2025
detailed description
This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety, tolerability and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with KRAS G12C mutant NSCLC who have been exposed to prior G12C inhibitor and experienced progressive disease.
official title
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol